Shares in Vertex have soared after the company announced that tens of thousands of cystic fibrosis (CF) patients could benefit from treatment for the first time. The company is a pioneer in ...
Vertex has launched the next phase of its plan for the cystic fibrosis market, filing for approval of a three-drug combination in the US to sit alongside its one- and two-drug products.
According to a Vertex spokesperson, the drug is seeing strong initial market adoption, with growing payer coverage and ...
The Motley Fool on MSN16d
Where Will Vertex Pharmaceuticals Be in 10 Years?The past decade has been a game-changing one for Vertex Pharmaceuticals (NASDAQ: VRTX). The biotech won approval for its first cystic fibrosis (CF) drug -- Kalydeco -- back in 2012 and has since ...
The genetic condition cystic fibrosis had no treatments on the NHS before 2019 and a Daily Express campaign - now a miracle ...
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF ...
In March 2025, Vertex Pharmaceuticals Incorporated announced a study is to evaluate the safety, and tolerability and efficacy ...
Vertex Pharmaceuticals (NASDAQ:VRTX), a leading biopharmaceutical company with a market capitalization of $131.2 billion, has been making significant strides in the treatment of cystic fibrosis ...
Although cystic fibrosis is a single gene mutation, there are more than 1,000 different ways the CFTR gene can mutate in ...
7d
From today, the updated indication for TRIKAFTA is as follows: TRIKAFTA is indicated for the treatment of cystic fibrosis in patients aged 2 years and older who have at least one F508del mutation in ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback